ArticleThe Journal of clinical investigation2023
T-BET and EOMES sustain mature human NK cell identity and antitumor function.
Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- HDAC6 orchestrates NK cell maturation and antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- Immunosenescence in systemic and multi-organ aging: mechanisms, inter-organ crosstalk, and translational opportunities.npj aging · 2026Review
- Inducible T-bet deletion reveals tissue-specific requirements in NKp46+ ILC immunobiology and response to murine cytomegalovirus.Nature communications · 2026Article
- Integrative transcriptomic profiling reveals NK cell exhaustion-associated prognostic genes and identifies CSF1 as a key immunoregulatory target in hepatocellular carcinoma.Biology direct · 2026Article
- Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy.Signal transduction and targeted therapy · 2026Article
- Transcriptional networks weaving natural killer anti-tumor immune response.Molecular cancer · 2026Review
- A systems immunology approach reveals divergent immune profiles of RSV and SARS-CoV-2 infections in infants.Science translational medicine · 2026Article
- Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans.Immunology and cell biology · 2026Article
- Role of tumor microenvironment in regulator of tumor progression and immunotherapy.Discover oncology · 2026Review
- Article
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- VNUT-mediated ATP release suppresses T helper 1 (TScience advances · 2025Article
- Reprogramming natural killer cells in the tumor microenvironment: Challenges and therapeutic opportunities.Cytokine & growth factor reviews · 2025Review
- Mapping NK cell diversity in response to COVID-19 and mRNA vaccination.Scientific reports · 2025Article
- Single-cell RNA sequencing reveals altered immune and stromal landscape in primary and liver metastasis of gastric cancer.Biochemistry and biophysics reports · 2025Article
- Immunosenescence: signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features.Nature communications · 2025Article
- Single-cell analysis of pig lung leukocytes and their response to influenza infection and oseltamivir therapy.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Oxymatrine and astragaloside IV co-loaded liposomes: Scale-up purposes and their enhancement of anti-PD-1 efficacy against breast cancer.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 2 institutions in 1 country.
Funding
Abstract
Since the T-box transcription factors (TFs) T-BET and EOMES are necessary for initiation of NK cell development, their ongoing requirement for mature NK cell homeostasis, function, and molecular programming remains unclear. To address this, T-BET and EOMES were deleted in unexpanded primary human NK cells using CRISPR/Cas9. Deleting these TFs compromised in vivo antitumor response of human NK cells. Mechanistically, T-BET and EOMES were required for normal NK cell proliferation and persistence in vivo. NK cells lacking T-BET and EOMES also exhibited defective responses to cytokine stimulation. Single-cell RNA-Seq revealed a specific T-box transcriptional program in human NK cells, which was rapidly lost following T-BET and EOMES deletion. Further, T-BET- and EOMES-deleted CD56bright NK cells acquired an innate lymphoid cell precursor-like (ILCP-like) profile with increased expression of the ILC-3-associated TFs RORC and AHR, revealing a role for T-box TFs in maintaining mature NK cell phenotypes and an unexpected role of suppressing alternative ILC lineages. Our study reveals the critical importance of sustained EOMES and T-BET expression to orchestrate mature NK cell function and identity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.